GCG and short bowel syndrome: The use of such factors for ‘hollow organ’ gastrointestinal conditions is at a more preliminary stage although systemically administered glucagon-like peptide-2 (GLP-2) for the treatment of short bowel syndrome is now a clinically proven, albeit very expensive treatment (estimate $200,000 per quality adjusted life year).